Fig. 2From: Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE studyChange in serum ferritin from baseline (µg/L) by time point. M month, SD standard deviation, W week. Error bars represent the ± SD values for the respective mean valuesBack to article page